Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1678461 | 0.88 | P2RX7 (0.42) | P2RX7SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL1678173 | 0.87 | P2RX7 (0.41) | P2RX7SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL1677903 | 0.86 | CNR2 (0.42) | P2RX7SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL1677373 | 0.85 | P2RX7 (0.39) | P2RX7SMN1; SMN2ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1678127 | 0.85 | TLR2 (0.36) | P2RX7SMN1; SMN2ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7114834 | 0.85 | TLR2 (0.36) | P2RX7SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL14582633 | 0.84 | ALDH1A1 (0.33) | P2RX7ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL1678527 | 0.83 | P2RX7 (0.39) | P2RX7SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL1677924 | 0.83 | CYP2D6 (0.42) | P2RX7SMN1; SMN2ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1678433 | 0.83 | CYP2D6 (0.41) | P2RX7SMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201655-A1 | PHARMACEUTICAL COMPOSITION IMPROVING INTESTINAL ABSORPTION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | claimed |
| EP-2351566-A1 | PHARMACEUTICAL COMPOSITION IMPROVED IN ABSORPTION THROUGH INTESTINAL TRACT | Santen Pharmaceutical Co., Ltd (JP) | 2011-08-03 | — | — | EP | claimed |
| US-20080182881-A1 | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2008-07-31 | — | — | US | claimed |
| US-7345064-B2 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-03-18 | — | — | US | claimed |
| EP-1561749-B1 | TNF-Alpha production inhibitors for the treatment of autoimmune diseases | SANTEN PHARMACEUTICAL CO LTD (JP) | 2007-03-28 | — | — | EP | claimed |
| US-20060241155-A1 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2006-10-26 | — | — | US | claimed |
| EP-1561749-A1 | TNF-Alpha production inhibitors for the treatment of autoimmune diseases | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-10 | — | — | EP | claimed |
| EP-1302461-A1 | TNF-ALPHA PRODUCTION INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | claimed |
| US-20030032623-A1 | Tnf-alpha production inhibitors | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2003-02-13 | — | — | US | claimed |
| US-20110201655-A1 | PHARMACEUTICAL COMPOSITION IMPROVING INTESTINAL ABSORPTION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110201655-A1 | PHARMACEUTICAL COMPOSITION IMPROVING INTESTINAL ABSORPTION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110201655-A1 | PHARMACEUTICAL COMPOSITION IMPROVING INTESTINAL ABSORPTION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2351566-A1 | PHARMACEUTICAL COMPOSITION IMPROVED IN ABSORPTION THROUGH INTESTINAL TRACT | Santen Pharmaceutical Co., Ltd (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-2351566-A1 | PHARMACEUTICAL COMPOSITION IMPROVED IN ABSORPTION THROUGH INTESTINAL TRACT | Santen Pharmaceutical Co., Ltd (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20060229342-A1 | TNF-a production inhibitors | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| US-7098226-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| EP-1561749-A1 | TNF-Alpha production inhibitors for the treatment of autoimmune diseases | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-10 | — | — | EP | disclosed |
| US-20050014800-A1 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1302461-A1 | TNF-ALPHA PRODUCTION INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-20030032623-A1 | Tnf-alpha production inhibitors | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241155-A1 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | TNFRSF1A, FFAR4, NGFR | P2RX7 1408/4885SMN1; SMN2 4392/4885ALDH1A1 557/4885 |
| US-20060229342-A1 | TNF-a production inhibitors | TNF, TNFRSF1A, TNFRSF9 | P2RX7 1294/4885SMN1; SMN2 4499/4885ALDH1A1 950/4885 |
| US-20080182881-A1 | TNF-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | P2RX7 1605/4885SMN1; SMN2 4454/4885ALDH1A1 964/4885 |
| US-20110201655-A1 | PHARMACEUTICAL COMPOSITION IMPROVING INTESTINAL ABSORPTION | SLC10A2, NR1H4, SLC10A6 | P2RX7 1697/4885SMN1; SMN2 4040/4885ALDH1A1 2063/4885 |
| US-20050014800-A1 | Angiogenesis inhibitor | FLT4, KDR, FLT1 | P2RX7 1805/4885SMN1; SMN2 4717/4885ALDH1A1 1011/4885 |
| US-20030032623-A1 | Tnf-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | P2RX7 2242/4885SMN1; SMN2 4171/4885ALDH1A1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.